CL2017000578A1 - Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia - Google Patents

Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia

Info

Publication number
CL2017000578A1
CL2017000578A1 CL2017000578A CL2017000578A CL2017000578A1 CL 2017000578 A1 CL2017000578 A1 CL 2017000578A1 CL 2017000578 A CL2017000578 A CL 2017000578A CL 2017000578 A CL2017000578 A CL 2017000578A CL 2017000578 A1 CL2017000578 A1 CL 2017000578A1
Authority
CL
Chile
Prior art keywords
cancer
animal
amylase inhibitor
company
risk
Prior art date
Application number
CL2017000578A
Other languages
English (en)
Inventor
Yuanlong Pan
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2017000578A1 publication Critical patent/CL2017000578A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Animal Husbandry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

<p>LA INVENCIÓN PROPORCIONA TRATAMIENTO PARA EL CÁNCER, LA REDUCCIÓN DEL RIESGO DE CÁNCER O LA PREVENCIÓN DEL CÁNCER EN UN ANIMAL DE COMPAÑÍA, LOS MÉTODOS COMPRENDEN: IDENTIFICAR EL ANIMAL DE COMPAÑÍA QUE TIENE CÁNCER O EN RIESGO DE CÁNCER Y ALIMENTAR UNA FORMULACIÓN DIETÉTICA EN UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ PARA EL ANIMAL. LA FORMULACIÓN DIETÉTICA PUEDE COMPRENDER 20 % A 60 % DE PROTEÍNA; 10 % A 40 % DE GRASA; 10 % A 50 % DE CARBOHIDRATOS; Y 0,01 % A 5 % DE INHIBIDOR DE LA ALFA-AMILASA, Y OPCIONALMENTE 1 % A 50 % DE ALMIDÓN RESISTENTE. LA CANTIDAD TERAPÉUTICAMENTE EFICAZ PUEDE SER EFICAZ PARA EL TRATAMIENTO DEL CÁNCER, LA PREVENCIÓN DEL CÁNCER O LA REDUCCIÓN DEL RIESGO DE CÁNCER EN EL ANIMAL DE COMPAÑÍA MEDIANTE LA REDUCCIÓN DE LA GLUCOSA EN SANGRE POSTPRANDIAL DEL ANIMAL DE COMPAÑÍA EN COMPARACIÓN CON LA GLUCOSA EN SANGRE POSTPRANDIAL DEL ANIMAL DE COMPAÑÍA QUE INGIERE UNA FORMULACIÓN DIETÉTICA COMPARABLE QUE EXCLUYE EL INHIBIDOR DE LA ALFA-AMILASA.</p>
CL2017000578A 2014-09-19 2017-03-09 Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia CL2017000578A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052571P 2014-09-19 2014-09-19
US201462052573P 2014-09-19 2014-09-19

Publications (1)

Publication Number Publication Date
CL2017000578A1 true CL2017000578A1 (es) 2017-09-15

Family

ID=54238487

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000578A CL2017000578A1 (es) 2014-09-19 2017-03-09 Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia

Country Status (12)

Country Link
US (1) US20160082058A1 (es)
EP (1) EP3193897A1 (es)
JP (1) JP2017534576A (es)
CN (1) CN106659791A (es)
AU (1) AU2015319791A1 (es)
BR (1) BR112017003548A2 (es)
CA (1) CA2960347A1 (es)
CL (1) CL2017000578A1 (es)
CO (1) CO2017001899A2 (es)
MX (1) MX2017003217A (es)
RU (1) RU2017113154A (es)
WO (1) WO2016042518A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350206B2 (en) 2014-09-19 2019-07-16 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as BUB1 inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326650A1 (en) * 2016-11-28 2018-05-30 Fondazione di Religione e di Culto "Casa Sollievo Della Sofferenza" - Opera di San Pio da Pietrelcina Nutritional composition with resistant starch useful in the treatment of neoplastic diseases
WO2019112562A1 (en) 2017-12-05 2019-06-13 Hill's Pet Nutrition, Inc. Pet food composition and method of making pet food composition comprising enhanced levels of resistant starch
US20220053796A1 (en) * 2018-06-14 2022-02-24 Mars, Incorporated Composition for supporting animal with cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350206B2 (en) 2014-09-19 2019-07-16 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as BUB1 inhibitors

Also Published As

Publication number Publication date
CN106659791A (zh) 2017-05-10
MX2017003217A (es) 2017-05-23
AU2015319791A1 (en) 2017-02-23
CA2960347A1 (en) 2016-03-24
US20160082058A1 (en) 2016-03-24
RU2017113154A (ru) 2018-10-19
EP3193897A1 (en) 2017-07-26
WO2016042518A1 (en) 2016-03-24
BR112017003548A2 (pt) 2017-12-12
CO2017001899A2 (es) 2017-07-28
JP2017534576A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201790398A1 (ru) Способы лечения заболевания печени
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
CL2016002971A1 (es) Combinación.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
CL2017000578A1 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
MX372759B (es) Composiciones para usarse en mejorar la función renal.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
AR102412A1 (es) Composiciones y métodos para el tratamiento con hemopexina
BR112016015578A2 (pt) Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
MX383705B (es) Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida.